Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data COSCIENS Biopharma Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2017
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
0.91
0.92
26.9
0.53
3.65
5.26
14.6
7.14
9.59
7.5
Cost of revenue
0
0
2.1
0.41
2.32
0.09
6.02
4.21
4.86
4.85
Gross profit
0.91
0.92
24.8
0.12
1.34
5.17
8.56
2.94
4.73
2.65
Research and development
16.5
10.7
2.93
1.84
1.51
6.57
1.37
2.04
8.3
2.95
Selling, general and administrative
2.87
5.53
10.4
10.1
Selling and marketing
6.75
5.1
3.11
1.21
1.13
1.35
Operating income
-29.5
-23.1
9.84
-10.2
-5.71
-8.67
4.32
-4.63
-18.3
-10.7
Interest expense
0.14
0.14
0.13
0.17
Pre-tax income
-25
-20.3
9.64
-6.23
-4.72
-8.48
4.53
-4.37
-15.2
-10.3
Income tax
0
-3.48
5.45
-0.19
0.4
-0.11
1.08
-0.89
0.08
0.01
Income from continuing operations
-25
-16.8
4.19
-6.04
Net income
-25
-16.8
4.19
-6.04
-5.12
-8.37
3.45
-3.49
-15.3
-10.4
EBITDA
-29.3
-22.9
9.9
-5.47
-8.53
5.79
-3.19
-16.7
-9.49
EPS, basic
-34.62
-16.09
3.59
-5.03
-1.72
-1.01
1.87
-1.89
-5.93
-3.27
EPS, diluted
-34.62
-16.09
3.45
-5.03
-1.72
-1.01
1.86
-1.89
-5.93
-3.27
Balance sheet
FY2017
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
22
7.78
14.5
7.84
24.3
6.16
10.2
6.68
16.4
7.31
Receivables
0.37
0.22
0.29
0.66
1.68
1.31
0.73
0.29
2.36
1.26
Inventory
0.23
4.01
2.69
1.31
Total current assets
22.7
9.38
16.3
10.9
27.6
70.8
55.5
11.3
24
11.5
Property, plant and equipment
0.2
0.1
0.07
0.04
0.02
0.19
0.22
11.6
11
9.81
Lease right-of-use assets
0.58
0.16
0.15
Goodwill
7.55
8.61
8.21
8.05
8.82
8.13
Intangible assets
0.07
0.09
0.06
0.04
0.06
0.63
0.01
0.01
Total assets
31.7
22.2
25
20
37
80.1
27.8
23.7
35.1
21.4
Total current liabilities
4.2
5.77
5.6
5.66
4.74
7.77
7.04
1.31
7.22
3.61
Lease liabilities
0.26
0.05
0.03
0.07
1.4
2.04
1.93
Total liabilities
25.4
25
23.1
22.4
23.8
27.1
4.02
2.71
21.9
17.6
Paid-in capital
90.3
3.87
4.27
4.17
Retained earnings
-298
-314
-310
-317
-323
-335
-352
4.36
-12.1
-20.5
Shareholders' equity
6.21
-2.78
1.91
-2.46
13.2
21.9
23.8
21
13.2
3.84
Total equity
6.21
-2.78
1.91
-2.46
13.2
21.9
23.8
21
13.2
3.84
Total liabilities and equity
31.7
22.2
25
20
37
80.1
56
23.7
35.1
21.4
Cash flow statement
FY2017
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-25
-16.8
4.19
-6.04
-5.12
-8.37
3.45
-3.49
-15.3
-10.4
Depreciation and amortization
0.2
0.14
0.06
0.23
0.14
1.47
1.44
1.61
1.19
Cash from operations
-29
-22.9
6.83
-10.7
-4.13
-8.58
5.23
-2.58
-14.6
-8.47
Capital expenditures
-0.07
-0
-0.01
-0.03
-0.3
-0.72
-1.16
-0.71
Cash from investing
-0.31
0.31
-0.04
0.05
0.06
-0.66
-0.3
-0.73
25.1
-0.46
Stock issued
9.92
7.79
0
34.2
Cash from financing
9.92
8.03
0
3.89
20.5
51
-0.27
-0.36
-0.59
-0.41
Exchange rate effect
-0.05
0.36
-0.06
0.11
0.04
-0.77
-0.63
0.16
-0.21
0.25
Net change in cash
-19.5
-14.2
6.73
-6.67
16.4
41
4.03
-3.51
9.72
-9.09
Free cash flow
-29.1
-22.9
6.82
-8.61
4.93
-3.3
-15.7
-9.18
Key metrics
Worked out from the statements above. Latest values use fiscal 2025. Valuation uses the share price of $5.14 on August 11, 2026.
Profitability
Metric
Value
How it is calculated
Gross margin
35.3%
Gross profit / revenue.
Operating margin
-142.5%
Operating income / revenue.
EBITDA margin
-126.6%
EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin
-138.0%
Pre-tax income / revenue.
Net margin
-138.1%
Net income / revenue.
FCF margin
-122.4%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-113.0%
Cash from operations / revenue.
Return on equity (ROE)
-121.8%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-36.7%
Net income / average total assets.
R&D / revenue
39.3%
Research and development expense / revenue.
SG&A / revenue
134.2%
Selling, general and administrative expense / revenue.
Capex / revenue
9.4%
Capital expenditures / revenue.
D&A / revenue
15.8%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
-21.8%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
-19.9%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
15.5%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Gross profit growth, 1y
-44.0%
Gross profit vs the same period a year earlier. Only from a positive base.
Gross profit CAGR, 3y
-32.4%
Compound annual growth of gross profit over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Gross profit CAGR, 5y
14.7%
Compound annual growth of gross profit over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Book value growth, 1y
-70.8%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
-45.6%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
-21.9%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
-38.9%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-8.4%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
-10.3%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
3.18x
Current assets / current liabilities.
Quick ratio
2.37x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
2.02x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
EPS, basic
-$3.27
Net income per basic share, as reported (split-adjusted).
Valuation
Metric
Value
How it is calculated
Market cap
$16.4M
Share price x shares outstanding.
Enterprise value
$9.1M
Market cap + total debt - cash - short-term investments.
P/S
2.18x
Market cap / revenue.
P/B
4.26x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
4.26x
Market cap / tangible book value, when positive.
EV/Sales
1.21x
Enterprise value / revenue.
FCF yield
-56.1%
Free cash flow / market cap.
Earnings yield
-63.3%
Net income / market cap (the inverse of P/E).
What was COSCIENS Biopharma Inc.'s revenue in fiscal 2025?
COSCIENS Biopharma Inc. reported revenue of $7.5M for fiscal 2025, 21.8% lower than the year before.
Was COSCIENS Biopharma Inc. profitable in fiscal 2025?
No. It reported a net loss of $10.4M.
How much free cash flow did COSCIENS Biopharma Inc. generate in fiscal 2025?
Cash from operations of $8.5M minus capital expenditures of $706.0K left free cash flow of -$9.2M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.